News Category
Helus Pharma's appointment of Michael Halstead as CEO signals strategic leadership as the company advances its lead candidate HLP003 through Phase 3 t...
Website Rental Coaching, founded by Luke Van Der Veer, has expanded its local SEO training program to 14 countries, now serving 467 students globally,...
Ireland has banned electroshock treatment on minors under its new Mental Health Act, a move praised by human rights advocates as a significant step in...
Helus Pharma announced fiscal 2026 financials and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data expected i...
Helus Pharma announced the closing of a $50 million public offering to fund Phase 3 trials for HLP003 in major depressive disorder and other pipeline ...
Helus Pharma announced a $50 million public offering to advance its late-stage programs for major depressive disorder, generalized anxiety disorder, a...
Helus Pharma announced that its Phase 3 APPROACH trial for HLP003, a novel serotonergic agonist for major depressive disorder, has surpassed 86% enrol...
Helus Pharma announces its Chief Medical Officer will participate in a fireside chat at a key industry conference, highlighting the company's progress...
Craig Munro Wilson's 'Baptize America' examines the 1820 Campbell-Walker debate, arguing it was pivotal in defining American Christianity's identity, ...
Helus Pharma corrected its April 28, 2026 release regarding its partnership with TARA Mind, removing references to Veterans Exploring Treatment Soluti...
Helus Pharma appoints Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, bolstering expertise in biotechnology and CNS drug d...
Helus Pharma announced the immediate resignation of CEO Michael Cola at the board's request, with co-founder Eric So stepping in as interim CEO to ens...
Helus Pharma announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, leveraging his 20+ years of neuroscience leaders...
The first European data center powered by a microgrid has launched near Dublin, operating independently from the national grid, addressing energy dema...
Helus Pharma announced positive topline Phase 2 results for HLP004 as an adjunctive treatment for generalized anxiety disorder, showing significant sy...
Helus Pharma announced the appointment of Dr. Freda Lewis-Hall to its board and as chair of its Scientific Advisory Committee, bringing over 40 years ...
Helus Pharma announced positive Phase 2a results for SPL026, published in Nature Medicine, demonstrating significant and clinically meaningful reducti...
Helus Pharma reported Q3 2025 financial results, highlighting progress in its HLP003 Phase 3 program for major depressive disorder and HLP004 Phase 2 ...
Helus Pharma announced the appointment of Michael Cola as CEO, effective immediately, as the company advances toward critical data readouts for its de...
Fully Promoted achieved year-over-year sales growth, signed 57 new franchise agreements, and added master franchise partners in India, Ireland, and Ca...
